CLINICAL & PIPELINE·Drug Approval
KYOWA KIRIN's POTELIGEO Secures Latest FDA Labeling Approval for Orphan Drug MOGAMULIZUMAB-KPKC
KYOWA KIRIN's MOGAMULIZUMAB-KPKC (POTELIGEO) received a supplemental FDA labeling approval on February 19, 2026, reinforcing its orphan drug status. This marks the latest in a series of regulatory updates since its 2018 New Molecular Entity approval. Decision-makers must monitor these ongoing revisions for their implications on regulatory compliance, supply chain adjustments, and market strategy for this monoclonal antibody.
90-Day Activity